FDA Advisers Clear Moderna's mRNA Flu Shot, Leaving a Contentious Approval to the Agency

The Food and Drug Administration's independent vaccine advisers have handed the agency a decision it can no longer defer. Meeting on June 18, the Vaccines and Related Biological Products Advisory Committee voted 9-0, and then 9-0 again, that the benefits of Moderna's investigational mRNA influenza vaccine outweigh its risks for adults aged 50 and older. The twin votes, one covering adults 50 to 64 and a second covering those 65 and older, leave the FDA with a August 5 target date to rule on what would be the first mRNA-based seasonal influenza product ever licensed in the United States.

What makes the endorsement notable is not the arithmetic, which was as lopsided as advisory votes get, but the path that preceded it. The same application had been rejected out of hand only months earlier, and the reversal that put it back before the committee exposed a widening fault line inside the nation's principal drug regulator over the mRNA platform itself.

Advisers vote, nearly as one

The panel, known by the shorthand VRBPAC, was asked a narrow benefit-risk question rather than a recommendation to approve, the customary framing for such meetings. On both counts the answer was the same. According to STAT, which covered the session, the committee endorsed the vaccine, marketed by Moderna as mFLUSIVA and designated in development as mRNA-1010, for both age brackets under review.

FDA staff signaled that the two groups could travel different regulatory routes to market. The younger cohort, adults 50 to 64, would likely proceed through the traditional licensing pathway, while the 65-and-older group could be cleared under an accelerated pathway. That distinction is less exotic than it sounds. During the public comment period, Wellington Sun, a former FDA official who had subsequently worked for Moderna, observed that several influenza vaccines already on the market were licensed through accelerated pathways, undercutting any suggestion that the approach would be a departure for flu products.

Evidence before the panel

The committee's deliberations rested on a large Phase 3 program whose results were published in the New England Journal of Medicine. The pivotal trial enrolled tens of thousands of adults across multiple countries and measured the mRNA candidate against a licensed standard-dose comparator. Reported efficacy figures included the following:

• A relative reduction of roughly 26.6 percent in RT-PCR-confirmed influenza-like illness versus the standard-dose comparator in adults 50 and older, according to figures cited by BioPharm International.
• A higher relative efficacy, reported at 47.9 percent, when the endpoint was widened to healthcare-seeking outcomes such as emergency department visits, urgent care and hospitalizations.
• Strain-specific performance against the influenza A and B lineages included in the formulation, with each contributing to the pooled result.

Those numbers are the crux of the scientific case. A vaccine that lowers laboratory-confirmed illness by roughly a quarter, and that performs still better against the more severe outcomes that drive hospital utilization, addresses a real gap. Standard-dose influenza vaccines have long delivered uneven protection, particularly in older adults whose immune responses wane with age, and the annual toll of seasonal influenza in that population remains substantial.

Refusal, then reversal

The road to the June vote was anything but routine. In February 2026, then-CBER director Vinay Prasad issued a rare refusal-to-file letter, declining even to accept Moderna's application for review. Prasad's stated objection centered on trial design, specifically the company's use of a standard-dose rather than a high-dose influenza vaccine as the comparator in its pivotal study. A refusal to file is an uncommon administrative step, and applying it to a vaccine backed by a large published trial drew immediate criticism from parts of the scientific community.

The FDA reversed course within days. Following public backlash and a formal Type A meeting between the company and the agency, the application was accepted, and the process that culminated in the June endorsement resumed. Prasad, who had been a prominent internal skeptic of the mRNA platform, subsequently departed his role at the Center for Biologics Evaluation and Research. The episode was widely read as a test of whether individual leadership views could override the agency's established review machinery, and, for this product at least, the machinery reasserted itself.

The committee's task was to weigh benefit against risk on the evidence before it, and on that question the vote was unanimous in both age groups under review.

Politics swirls around mRNA

The Moderna review did not unfold in a vacuum. It coincided with a broader recalibration of federal vaccine policy under Health and Human Services Secretary Robert F. Kennedy Jr., a longstanding critic of mRNA technology. Reporting from multiple outlets has documented a run of contested decisions and personnel turnover at the FDA and its advisory bodies over the past year, developments that lent the flu-shot vote a significance beyond its immediate subject.

For the mRNA field, the stakes are structural. The platform's defenders argue that its speed and adaptability, demonstrated during the pandemic, make it well suited to a pathogen that mutates as readily as influenza, where formulations must be updated annually to track circulating strains. Skeptics have pressed questions about long-term safety data and have argued that established, non-mRNA options already meet the need. VRBPAC's near-unanimous endorsement does not settle that debate, but it does place the weight of the agency's own expert panel on one side of it.

August's decision, and its hinge

The advisory vote is a recommendation, not a ruling. The FDA is not bound by it, though the agency departs from such panels only occasionally, and rarely when the vote is unanimous. The PDUFA goal date of August 5 gives the agency a firm deadline to issue its determination for the 2026-27 respiratory season. Several threads bear watching in the interim:

• Whether the FDA licenses the vaccine for the full 50-and-older population the committee endorsed, or narrows the indication.
• Whether the agency adopts the split pathway that staff outlined, with traditional licensure for the younger group and accelerated licensure for the older one.
• How the Centers for Disease Control and Prevention's own advisers subsequently frame recommendations for use, a separate step that shapes access and insurance coverage.
• Whether an approval, if granted, arrives early enough to matter for fall vaccination campaigns.

For Moderna, an approval would validate a bet on extending its mRNA franchise beyond COVID-19 into the far larger and more durable seasonal influenza market. For the FDA, the decision is a chance to demonstrate that a fraught and public regulatory detour ended where the evidence pointed. The committee has spoken. The agency's answer, due by August 5, will indicate how much that evidence still governs.

This account is drawn from reporting by STAT, NPR, BioPharm International and BioPharma Dive, together with published trial results in the New England Journal of Medicine, and is a draft prepared for editorial verification.